Paula A. Johnson - 13 Aug 2026 Form 4 Insider Report for Maze Therapeutics, Inc. (MAZE)

Reporting relationship: Director
Issuer ticker: MAZE
Reported as of: 13 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Aug 2026, 16:51:08 UTC
Prior SEC filing: 27 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Courtney Phillips, as attorney-in-fact

Key filing fact

Paula A. Johnson filed Form 4 for Maze Therapeutics, Inc. (MAZE) on 17 Aug 2026.

Key facts

This page summarizes Paula A. Johnson's Form 4 filing for Maze Therapeutics, Inc. (MAZE).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 17 Aug 2026, 16:51.

Change

Previous filing in this sequence was filed on 27 Apr 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001341161 Primary reporting owner

Johnson Paula A

Relationship: Director
Address: C/O MAZE THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO
Signature: /s/ Courtney Phillips, as attorney-in-fact
Signature date: 17 Aug 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MAZE transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +36,000
Change %
Price: $0.000000^*
Shares after: 36,000
Date: 13 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 36,000
Exercise price: $27.66
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option shall vest as to 1/36th of the total award monthly, with the first tranche vesting on September 13, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.